Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
Explore the evolving landscape of CAR-T cells and bispecific antibodies in the management of haematological malignancies at this European School of Haematology (ESH) event. With a focus on acute lymphoblastic leukaemia, lymphoma, and myeloma, this conference will offer expert insights into the clinical use, risks, and benefits of emerging therapies.
Through interactive case-based discussions and a problem-solving approach, participants will examine:
CAR-T and bispecific antibody treatments across indications.
Comparative effectiveness of bispecific vs. cellular therapies (including T cells, NK cells, and transplant strategies).
Access and affordability of these treatments globally.
Future applications in other blood cancers and solid tumours.
–
